Generating destination analysis
Compass Direction
Earnings IntelligenceAI-Powered
Compass Score
Unlock Full NTLA Analysis
UpgradeKey Numbers
Market Cap
$3B
P/E
N/A
Revenue Growth
0.0%
Gross Margin
N/A
ROE
N/A
About Intellia Therapeutics
As a small-cap biotech company trading on the NASDAQ, Intellia Therapeutics has established itself, with direct, concentrated exposure to the biotech and genomics theme. In-vivo CRISPR gene-editing leader with promising liver disease candidates. With a $3B market capitalization and no current profitability, the company demonstrates top-line contraction at 0% year-over-year.
Expert Coverage
Price & Technical Analysis
Price vs 200DMA
DMA Convergence
50 DMA
200 DMA
More in Biotech & Genomics
ARK Genomic Revolution ETF
ETF focused on companies advancing genomics, gene editing, and therapeutics.
DexCom Inc.
Continuous glucose monitoring leader expanding beyond diabetes management.
Alnylam Pharmaceuticals
RNA interference therapeutics leader with approved treatments for rare diseases.
Eli Lilly and Company
Pharma giant leading the GLP-1 revolution with Mounjaro and Zepbound weight-loss drugs.